CereVasc News and Activities

View the org chart displaying its 19 main executives

Most searched biographies at CereVasc

• Daniel Levangie, Chairman, President and Chief Executive Officer
• Patrick Sullivan, Co-Founder
• Carl Heilman, Director

Create your alert
to follow the executive moves at CereVasc.

CereVasc has 1,235 competitors including Thermo Fisher Scientific (United States (USA)), Philips (Netherlands) and Medtronic (Ireland).

Popular M&A news in Medical Equipment

• Niowave has just announced a $70 Million fundraising (posted on June 2 2026).
• The new name of Edap Tms is FocalTherics. (posted on June 1 2026).
• FocalTherics is now listed under ticker FOCL. (posted on May 31 2026).

Popular contacts in Medical Equipment

• Kweli Thompson - Executive Vice President and President, Neuroscience Portfolio at Medtronic
• Jacob Thaysen - Chief Executive Officer and Director at Illumina
• Ivan Tornos - Chairman, President and Chief Executive Officer at Zimmer Biomet

Learn more about the Medical Equipment industry

Press releases by CereVasc

• CereVasc, Inc. Announces Results of Groundbreaking Clinical Study of the eShunt® System in the Treatment of Elderly Patients with Normal Pressure Hydrocephalus | CereVasc | Neurological Disease Device Company
• CereVasc Receives Approval for STRIDE Clinical Trial of the eShunt® System for the Treatment of Elderly Patients with Normal Pressure Hydrocephalus in Argentina | CereVasc | Neurological Disease Device Company
• CereVasc Announces First Enrollment in STRIDE Clinical Trial of the eShunt® System for Normal Pressure Hydrocephalus | CereVasc | Neurological Disease Device Company
• CereVasc Announces Enrollment of the 50th Patient in Pilot Studies of the eShunt® System for Normal Pressure Hydrocephalus | CereVasc | Neurological Disease Device Company
• CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus | CereVasc | Neurological Disease Device Company
• CereVasc Receives FDA IDE Approval for the STRIDE Pivotal Study of the eShunt System for Treatment of Normal Pressure Hydrocephalus | CereVasc | Neurological Disease Device Company
• CereVasc Receives FDA IDE Approval to Expand its Clinical Study of Patients with Normal Pressure Hydrocephalus Utilizing the Generation 2 eShunt® System | CereVasc | Neurological Disease Device Company
• eShunt® System | CereVasc Press | CereVasc | Neurological Disease Device Company
• View more press releases Close

Social media about CereVasc

• CereVasc on Wikipedia, Google News & Yahoo Finance
• CereVasc on LinkedIn, X (Twitter) & YouTube